fusion protein, polynucleotide, construct, vector, host cell or organism, pharmaceutical composition or vaccine, use of fusion protein, method for preventing or treating hev infection or diseases associated with hev infection, method for preventing or treating influenza virus infection and diseases associated with influenza virus infection, method for improving the immunogenicity of a target protein and use of crm197 or a fragment thereof
Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
